COMMUNIQUÉS West-GlobeNewswire

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
25/03/2026
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
25/03/2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund [...]
BeyondSpring Files 2025 Annual Report on Form 10-K
25/03/2026
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and [...]
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
25/03/2026
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 [...]
American Nurses Enterprise Launches 2026–2030 Strategic Plan, Charting a Bold New Direction for the Future of Nursing
25/03/2026
Marking ANA's 130th Anniversary, ANE Sets a New Strategic Course to Advance the Nursing Profession SILVER SPRING, MD, March 25, 2026 (GLOBE NEWSWIRE) -- The American Nurses Enterprise (ANE), the unifying force behind [...]
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
25/03/2026
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
25/03/2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the [...]
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
25/03/2026
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the [...]
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
25/03/2026
Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE [...]
LogicMark, Inc. Announces Strong Fourth Quarter and Full Year 2025 Results
25/03/2026
Quarterly Revenue Surges 36% as Gross Margin Expands to 69.8% LOUISVILLE, Ky., March 25, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK) (the “Company”), a provider of personal safety and emergency response systems [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
25/03/2026
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune [...]
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier
25/03/2026
DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie [...]
Financière de Tubize - Convocation des actionnaires à l’Assemblée Générale Ordinaire du 24 avril 2026
25/03/2026
Convocation des actionnaires à l’Assemblée Générale Ordinaire du 24 avril 2026 Les actionnaires sont invités à prendre part à l’assemblée générale ordinaire qui se tiendra le 24 avril 2026 à 11 heures à 1070 Bruxelles ( [...]
Financière de Tubize - Convening of the ordinary general meetings of shareholders of April 24, 2026
25/03/2026
Convening of the Ordinary Meeting of shareholders of 24 April 2026 The shareholders are invited to attend the ordinary general meeting, which will take place on Friday 24th of April 2026 at 11:00AM at 1070 Brussels ( [...]
Catalyst MedTech Establishes Full Access Neurology Solution as the Industry Standard for Brain PET Implementation in the U.S.
25/03/2026
Full Access Neurology is a proven, end-to-end optimized Brain PET clinical solution—built for real-world implementation PITTSBURGH, March 25, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear [...]
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
25/03/2026
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior [...]
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
25/03/2026
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin [...]
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
25/03/2026
SPRING, Texas, March 25, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature , of [...]

Pages